Product Search |
|
| Input Product Name Or Cas No. |
Category |
Products |
S-(naphthalen-2-yl) 2-methylprop-2-eneth |
2-[[1,3-Bis(methacryloyloxy)propan-2-ylo |
Methyl 2-[[(1-oxo-2-propen-1-yl)oxy]meth |
Phenol, 3,3′-[1,5-naphthalenediylbis(o |
3,3′-[1,4-Naphthalenediylbis(oxy)]bis[ |
(Tetrahydro-2-oxo-3-furanyl)methyl 2-met |
bis(4-((tert-butyldimethylsilyl)oxy)phen |
3-(acryloyloxy)-2-hydroxypropyl 4-vinylb |
4,4-bis(neopentyloxy)butyl methacrylate |
Phenol, 2,2′-[(6-chloro-1,3,5-triazine |
2-[[[Bis(2-hydroxyethyl)amino]carbonyl]a |
3,3′-[(2,6-Naphthalenediyl)bis(oxy)]bi |
1-(4-Fluorophenyl)-1-methylethyl 2-prope |
Benzoic acid, 4-ethenyl-, 1-(2-cyclohexy |
4-[[(4-Methylphenyl)sulfonyl]oxy]cyclohe |
1H-1,2,4-Triazole-1-carboxylic acid, 2,2 |
5,5′-Bis([1,1′-biphenyl]-4-yl)-2,2†|
2-(Methylamino)ethyl 2-methyl-2-propenoa |
2-Benzofurancarboxylic acid, 6-methoxy-, |
4,4′-Octylidenebis[phenol] |
1,3-Bis(1,1-dimethylethyl) 2-(2,3-dihydr |
6-Hydroxy-1-naphthalenesulfonic acid |
9,9-Dimethyl-9H-fluoren-2-ol |
2-Chloro-4,6-diethoxy-1,3,5-triazine |
1,2-Diethyl-3,5-pyrazolidinedione |
2-[(Methylsulfonyl)oxy]ethyl 2-propenoat |
4,4′-Oxybis[2-methylphenol] |
1-phenylethane-1,2-diyl diacrylate |
2,4-bis(benzyloxy)-6-chloro-1,3,5-triazi |
4,4′-Cyclopentylidenebis[2-methylpheno |
4-(((benzyloxy)carbonyl)oxy)benzoic acid |
1,2-dibenzylpyrazolidine-3,5-dione |
6-(4-Aminophenoxy)-3-pyridinamine |
4-Iodo-N-phenylbenzenesulfonamide |
Ethyl 1,3-dihydro-1,3-dioxo-5-isobenzofu |
6-Methoxy-1,3,5-triazine-2,4(1H,3H)-dion |
6-Chloro-3,4-dihydro-4-oxo-2H-1-benzothi |
3-[[4-(Dimethylamino)phenyl]methylene]-1 |
4,4′-[1,5-Naphthalenediylbis(oxy)]bis[ |
3,4,5-Trihydroxybenzonitrile |
[1,1′-Biphenyl]-4-ol, 4-propanoate |
Tetrahydro-1H-pyrazolo[1,2-a]pyridazine- |
4-Bromo-2-ethylthiazole |
3,4,5-Trihydroxy-N-propylbenzamide |
4,6-Diethoxy-1,3,5-triazin-2(1H)-one |
propane-2,2-diylbis(4,1-phenylene) dipro |
1-(2-Chloroethyl)-1H-pyrrole-2,5-dione |
3,3′-Dibromo[2,2′-bithiophene]-5,5†|
4,6-Bis(phenylmethoxy)-1,3,5-triazin-2(1 |
3-isopropylpyrrolidine-2,5-dione |
|
Products |
| Catalogue Number |
Products |
CAS No. |
Assay |
| NX51897 | PF-04217903 | 1159490-85-3 | 95% |
| NX51898 | CUDC-101 | 1012054-59-9 | 95% |
| NX51899 | A-966492 | 934162-61-5 | 95% |
| NX51900 | AZ-23 | 915720-21-7 | 95% |
| NX51901 | Bafetinib | 887650-05-7 | 95% |
| NX51902 | N,N-Dimethyl-1,4-phenylenediamine oxalate | 62778-12-5 | 95% |
| NX51903 | Elvitegravir | 697761-98-1 | 95% |
| NX51904 | Akt-I-1,2 | 473382-48-8 | 95% |
| NX51905 | Akt-I-1 | 473382-39-7 | 95% |
| NX51906 | JNJ-7706621 | 443797-96-4 | 95% |
| NX51907 | Betrixaban | 330942-05-7 | 95% |
| NX51908 | N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-Butenamide | 326894-84-2 | 95% |
| NX51909 | Vatalanib dihydrochloride | 212141-51-0 | 95% |
| NX51910 | Fingolimod hydrochloride | 162359-56-0 | 95% |
| NX51911 | Fingolimod | 162359-55-9 | 95% |
| NX51912 | 4,N,N-Trimethylaniline | 99-97-8 | 95% |
| NX51913 | 2-Nitrobenzoyl chloride | 610-14-0 | 95% |
| NX51914 | N-(2-hydroxypropyl)aniline | 3077-13-2 | 95% |
| NX51915 | 2-amino-5-nitrobenzenesulfonic acid | 96-75-3 | 95% |
| NX51916 | N,N-diethyl-2-methyl-benzenamine | 606-46-2 | 95% |
| NX51917 | 3-amino-5-(trifluoromethyl)Benzonitrile | 49674-28-4 | 95% |
| NX51918 | N,N-bis-(2-hydroxy-propyl)-p-toluidine | 38668-48-3 | 95% |
| NX51919 | N-methyl-4-methylaniline | 623-08-5 | 95% |
| NX51920 | 4-bromo-3-(trifluoromethoxy)Benzaldehyde | 1221716-04-6 | 95% |
| NX51922 | trans-4-tert-Butylcyclohexanecarboxylic Acid | 943-29-3 | 95% |
| NX51923 | 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic Acid Ethyl Ester | 112811-71-9 | 95% |
| NX51924 | Sodium methacrylate | 5536-61-8 | 95% |
| NX51925 | 2,3,4,5-tetrahydro-5-methyl-1H-Pyrido[4,3-b]indol-1-one | 122852-75-9 | 95% |
| NX51926 | 5,6-dihydro-4-(2-methyl-2-phenylhydrazinyl)-2(1H)-Pyridinone | 139122-76-2 | 95% |
| NX51928 | 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo-3-Quinolinecarboxylic acid | 127294-70-6 | 95% |
|
|
|
|